Novo Nordisk A/S has announced its agreement to acquire Cardior Pharmaceuticals in a deal worth up to $1 billion. The acquisition is part of Novo Nordisk’s strategy to expand its portfolio in treatments for cardiovascular disease. Cardior Pharmaceuticals is a company developing therapies that focus on targeting microRNA, with potential applications in the treatment of various cardiovascular conditions. As part of the deal, Novo Nordisk will make an upfront payment to Cardior, with additional payouts contingent upon the achievement of specific milestones. By acquiring Cardior Pharmaceuticals, Novo Nordisk aims to further strengthen its position in the cardiovascular disease market and provide innovative solutions for patients.